AbCellera Biologics Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
AbCellera announced two T-cell engager (TCE) collaborations: Jazz Pharmaceuticals ($84M upfront: $56M received Q2, $28M for third program within 12 months, up to $792M per program in milestone payments) and Vertex Pharmaceuticals ($28M upfront for autoimmune research). Q2 2026 net loss was $55.4M vs. $34.7M in Q2 2025; revenue fell 76% to $4.1M (from $17.1M). Cash and marketable securities: $565M; total liquidity including government funding: $675M. ABCL635 Phase 2 readout expected August 2026.
Why this rating
Partnerships add $112M cash (14% of market cap) and extend runway, offsetting revenue decline and higher losses. Moderate trajectory impact relative to company size.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.